ABSTRACT
Background: Dengue fever is one of the most common arboviral mediated outbreaks reported with increased prevalence year after year with considerable morbidity and mortality in hadoti region. the aim to study various clinical and laboratory manifestations of Dengue fever admitted in MBS Hospital KOTA, with a diagnosis of Dengue fever according to WHO protocol from December 2018 to January 2020.Methods: Prospective observational study was undertaken among adult patients. 132 patients were studied and analysed. And diagnosis was confirmed with Dengue IgM ELISA test. Other routine investigations done were routine hematological and biochemical investigations.Results: A total of 132 cases, out of which 95 cases of Dengue Fever (DF), 34 cases of dengue hemorrhagic fever and 3 cases of Dengue Shock syndrome, out of which Male: Female ratio was 2.1. and mean age of presentation was 37. Fever and myalgia were the most common finding (100%) followed by arthralgia and headache. Pruritus was found in 21 cases (15.9%) which carried a significant difference between DF and DHF (p value <0.05). Among the laboratory features, thrombocytopenia and hematocrit were found to be statistically significant in DHF patients (p value <0.05). Mean platelet count was 0.71 lakhs/mm3. Leukopenia in 40(30.3%) cases. Raised Serum Aminotransferase level, AST (>40 IU/L) was seen in 39 cases (29.54%.). Pleural effusion was seen in 4 cases (3%), of which 3 cases of DHF and 1 case of DSS. Ascites in 6 cases (4.8%), all cases belong to DHF. Gall bladder wall thickening was seen in 28 cases (21.21%) of which 20 cases (54.04%) were of DHF. Melena was the most common bleeding manifestation. Skin rash was found to be positive in 40.5% cases. Hess test was positive in 4 cases (10.8% of DHF).Conclusions: Incidence of dengue fever is on the rise in hadoti region and one of the most important differential diagnosis of patients presenting with fever during monsoon and post monsoon seasons.
ABSTRACT
Background: Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent decrease in bone mineral density (BMD) and increase in bone fragility and susceptibility to fracture. Hence; we planned the present study to assess the effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects. Methods: The present study included assessment of effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects. A total of 120 postmenopausal women were included in the present study. All the subjects were broadly divided into two broad groups with 60 subjects in each group; Group A: Subjects who were given placebo for two years Group B: Subjects who were given raloxifene 60 mg/d for 2 years. Assessment of Risk of Postmenopausal Fracture in all the subjects was done by evaluating the bone mineral density (BMD) at two years follow-up time. All the results were compiled and assessed by SPSS software. Results: Non- significant results were obtained while comparing the adverse effects among subjects of both the study groups. Overall incidence of new vertebral fractures among subjects of group A and group B included 6 and 4 percent respectively. Significant results were obtained while comparing the incidence of new vertebral fractures among subjects of group A and group B respectively. Conclusion: Significant reduction in the risk of fractures occur under the influence of raloxifene in postmenopausal women with osteoporosis.